New Zealand markets closed

Intercept Pharmaceuticals, Inc. (ICPT)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
16.56-1.20 (-6.76%)
At close: 04:00PM EST
16.57 +0.01 (+0.06%)
After hours: 04:55PM EST
Full screen
Trade prices are not sourced from all markets
Previous close17.76
Open17.22
Bid16.59 x 900
Ask17.70 x 800
Day's range16.53 - 17.56
52-week range11.60 - 38.94
Volume874,289
Avg. volume875,434
Market cap489.298M
Beta (5Y monthly)1.41
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
All
News
  • GlobeNewswire

    Intercept Pharmaceuticals Provides Update on Phase 3 REVERSE Trial in Compensated Cirrhosis Due to NASH

    Study remains ongoing; top-line data anticipated in Q1 2022 versus near the end of the yearNEW YORK, Dec. 20, 2021 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that top-line data from its Phase 3 REVERSE trial will be delayed from our previous guidance of near the end of the year and is now expected in the first q

  • GlobeNewswire

    Intercept Announces Withdrawal of EMA Marketing Authorization Application for Obeticholic Acid for Advanced Liver Fibrosis Due to NASH

    NEW YORK, Dec. 09, 2021 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that it has formally notified the European Medicines Agency (EMA) of its decision to withdraw its Marketing Authorization Application (MAA) for obeticholic acid (OCA) for the treatment of liver fibrosis due to nonalcoholic steatohepatitis (NASH).

  • GlobeNewswire

    Intercept Announces New Long-Term Data Demonstrating Potential of Obeticholic Acid to Improve Transplant-Free Survival in Patients with PBC

    Analysis compares findings from the long-term safety extension of the Phase 3 POISE trial to PBC natural history data from the Global PBC and UK-PBC databases Results will be featured in a late-breaking podium presentation at The Liver Meeting® NEW YORK, Nov. 15, 2021 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced re